Evaluation of pharmacokinetic and pharmacodynamic profiles and tolerability after single (2.5, 5, or 10 mg) and repeated (2.5, 5, or 10 mg bid for 4.5 days) oral administration of ivabradine in healthy male korean volunteers

Clinical Therapeutics

Volumn 35, Issue 6, 2013, Pages 819-835

  Choi, Hee Youn ^a   Noh, Yook Hwan ^a   Cho, Sang Heon ^b   Ghim, Jong Lyul ^c   Choe, Sangmin ^d   Kim, Un Jib ^a   Ah Jung, Jin ^e   Bae, Kyun Seop ^a   Lim, Hyeong Seok ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inha University Hospital   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Pusan National University School of Medicine   (South Korea)

^e Samsung Medical Center   (South Korea)

Author keywords

Healthy individual; Ivabradine; Pharmacodynamics; Pharmacokinetics

Indexed keywords

IVABRADINE; PLACEBO; BENZAZEPINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG TOLERABILITY; DRUG URINE LEVEL; ECG ABNORMALITY; ELECTROCARDIOGRAM; FAINTNESS; HOLTER MONITORING; HUMAN; HYPERBILIRUBINEMIA; INJECTION SITE PHLEBITIS; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SOUTH KOREA; STEADY STATE; SUPRAVENTRICULAR PREMATURE BEAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG TOLERANCE; HEART RATE; ORAL DRUG ADMINISTRATION; VOLUNTEER; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BENZAZEPINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; HEART RATE; HUMANS; MALE; VOLUNTEERS; YOUNG ADULT;

EID: 84879459623     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.04.012     Document Type: Article

References (45)

1. Dyer A.R., Persky V., Stamler J., et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980, 112:736-749.
2. Kannel W.B., Kannel C., Paffenbarger R.S., et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987, 113:1489-1494.
3. Mensink G.B., Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J 1997, 18:1404-1410.
4. Kristal-Boneh E., Silber H., Harari G., et al. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 2000, 21:116-124.
5. Hjalmarson A., Gilpin E.A., Kjekshus J., et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990, 65:547-553.
6. Castagno D., Skali H., Takeuchi M., et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol 2012, 59:1785-1795.
7. Fosbol E.L., Seibaek M., Brendorp B., et al. Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: the DIAMOND study. Int J Cardiol 2010, 140:279-286.
8. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 2008, 153:1589-1601.
9. Custodis F., Schirmer S.H., Baumhakel M., et al. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 2010, 56:1973-1983.
10. Androulakis E., Tousoulis D., Papageorgiou N., et al. Heart rate as a therapeutic target in angina pectoris. Curr Pharm Des 2013, 19:1562-1568.
11. Hasenfuss G., Holubarsch C., Hermann H.P., et al. Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J 1994, 15:164-170.
12. Hori M., Okamoto H. Heart rate as a target of treatment of chronic heart failure. J Cardiol 2012, 60:86-90.
13. Gheorghiade M., Colucci W.S., Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003, 107:1570-1575.
14. Eisenberg M.J., Brox A., Bestawros A.N. Calcium channel blockers: an update. Am J Med 2004, 116:35-43.
15. Baruscotti M., Bucchi A., Difrancesco D. Physiology and pharmacology of the cardiac pacemaker ("funny") current. Pharmacol Ther 2005, 107:59-79.
16. Thollon C., Bidouard J.P., Cambarrat C., et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 1997, 339:43-51.
17. Camm A.J., Lau C.P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 2003, 4:83-89.
18. Thollon C., Cambarrat C., Vian J., et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994, 112:37-42.
19. DiFrancesco D., Camm J.A. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004, 64:1757-1765.
20. Borer J.S., Fox K., Jaillon P., et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003, 107:817-823.
21. Tardif J.C., Ford I., Tendera M., et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005, 26:2529-2536.
22. Ruzyllo W., Tendera M., Ford I., et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007, 67:393-405.
23. Swedberg K., Komajda M., Bohm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
24. Ceconi C., Freedman S.B., Tardif J.C., et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol 2011, 146:408-414.
25. Heusch G., Skyschally A., Schulz R. Cardioprotection by ivabradine through heart rate reduction and beyond. J Cardiovasc Pharmacol Ther 2011, 16:281-284.
26. Tardif J.C., O'Meara E., Komajda M., et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011, 32:2507-2515.
27. Mulder P., Barbier S., Chagraoui A., et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004, 109:1674-1679.
28. Procoralan: EPAR - Scientific Discussion. Servier Laboratories Ltd. Accessed March 25, 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000597/human_med_000995.jsp&mid=WC0b01ac058001d124.
29. Duffull S.B., Chabaud S., Nony P., et al. A pharmacokinetic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci 2000, 10:285-294.
30. Portoles A., Terleira A., Calvo A., et al. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol 2006, 46:1188-1194.
31. Vlase L., Neag M., Popa A., et al. Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. J Clin Pharm Ther 2011, 36:225-229.
32. Vlase L., Popa A., Neag M., et al. Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. Clin Drug Investig 2012, 32:533-538.
33. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med. 2001;47:45-50.
34. The Helsinki Declaration. Assist Inferm Ric. 2010;29:41-44.
35. François-Bouchard M., Simonin G., Bossant, Boursier-Neyret C. Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000, 745:261-269.
36. Funck-Brentano C., Jaillon P., Rate-corrected Q.T. interval: techniques and limitations. Am J Cardiol 1993, 72:17B-22B.
37. Luo S., Michler K., Johnston P., et al. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 2004, 37(Suppl):81-90.
38. Rowland M., Tozer T. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications 2011, Lippincott Williams & Wilkins, Philadalphia, Pa. 4th ed.
39. Shein-Chung C., Jen-Pei L Design and Analysis of Bioavailability and Bioequivalence Studies 2009, CRC Press, Boca Raton, Fla. 3rd ed.
40. Borer J.S. Clinical effect of 'pure' heart rate slowing with a prototype If current inhibitor: placebo-controlled experience with ivabradine. Adv Cardiol 2006, 43:54-64.
41. DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Curr Med Res Opin 2005, 21:1115-1122.
42. Borer J.S., Tardif J.C. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. Am J Cardiol 2010, 105:29-35.
43. Parakh N., Bhargava B. Rate control with ivabradine: angina pectoris and beyond. Am J Cardiovasc Drugs 2011, 11:1-12.
44. Bucchi A., Baruscotti M., DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol 2002, 120:1-13.
45. Cervetto L., Demontis G.C., Gargini C. Cellular mechanisms underlying the pharmacological induction of phosphenes. Br J Pharmacol 2007, 150:383-390.